respiratory syncytial virus (RSV) - Articles and news items

Ablynx initiates Phase IIb anti-RSV nanobody trial for infants

Industry news / 12 January 2017 / Niamh Marriott, Digital Editor

Topline results from this Phase IIb study to treat children with RSV with inhaled ALX-0171 are expected in the second half of 2018…

Study finds mobile phones used by hospital staff harbour viruses

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

A study from University Hospital of Saint-√Čtienne in France reveals that mobile devices are often also contaminated by viral RNA…

Positive top line results from ALX-0171 infant RSV study

Industry news / 4 May 2016 / Victoria White, Digital Content Producer

The study met its primary endpoint, demonstrating the favourable safety and tolerability profile of ALX-0171 when administered daily by inhalation…

Maternal immunisation

Blog / 3 March 2016 / Emmanuel Hanon, Senior Vice President, Head of Vaccines Research & Development, GSK

Here, GSK’s Emmanuel Hanon discusses maternal vaccination and how it has emerged as a promising public health strategy…

RSV treatment market to expand at ‘unprecedented levels’

Industry news / 13 January 2016 / Victoria White

The RSV treatment market will rise from approximately $640 million in 2014 to over $2.3 billion by 2024, says research and consulting firm GlobalData…

New data shows potential of ALS-008176 in RSV

Industry news / 19 November 2015 / Victoria White

In the study, treatment with ALS-00876 resulted in a significant reduction of viral load and faster viral clearance versus placebo…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+